RecruitingNCT06788717

MDR - Comprehensive Primary Revision Stems PMCF

Post-market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data of the Comprehensive® Primary Revision Stems (Implants and Instrumentation) - A Retrospective and Prospective Consecutive Series Study


Sponsor

Zimmer Biomet

Enrollment

59 participants

Start Date

Jun 19, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The objective of this retrospective and prospective consecutive series PMCF (Post Market Clinical Follow Up) study is to collect long-term data confirming safety, performance and clinical benefits of the Comprehensive Primary Revision Stems (implants and instrumentation) when used for shoulder arthroplasty at 1, 3, 5, 7 and 10 years.


Eligibility

Min Age: 18 YearsMax Age: 100 Years

Inclusion Criteria3

  • Patient must be 18 years of age or older.
  • Patient must be willing and able to follow directions.
  • Study devices must have been implanted following the surgical technique and IFU for the Comprehensive Revision Stem

Exclusion Criteria6

  • Off-label use.
  • Patient is a prisoner.
  • Patient is a current alcohol or drug abuser.
  • Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent.
  • Patient is unwilling to sign informed consent.
  • Uncooperative patient or patient with neurologic disorders who are incapable of following directions.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEComprehensive Primary Revision Stems

Comprehensive Primary Revision Stem (implants and instrumentation) when used for shoulder arthroplasty.


Locations(2)

Cedars Sinai Medical Center

Los Angeles, California, United States

Aalborg University Hospital

Aalborg, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06788717


Related Trials